Category Archives: Global News Feed


MediPharm Labs Expands Denmark Revenue Opportunity, Enters New Supply Agreement with DanCann Pharma

TORONTO, Sept. 25, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has entered into a new white-label supply agreement with DanCann Pharma A/S (“DanCann Pharma”). The company will be serviced by both GMP approved facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ third supply agreement for the export of finished products to Denmark expanding its revenue opportunity in an emerging medicinal cannabis market.

See the article here:
MediPharm Labs Expands Denmark Revenue Opportunity, Enters New Supply Agreement with DanCann Pharma

Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote…

-  NuGenHealth Software as a Service (SaaS) platform launch-  PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population

More here:
Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote...

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients…

Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D

View post:
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients...

EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO …

-- Jyseleca®  Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program --Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1

More here:
EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO ...

Zomedica Announces Shareholder Meeting Voting Results

ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”).

See the original post here:
Zomedica Announces Shareholder Meeting Voting Results

Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with…

-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children

See the article here:
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with...

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following virtual investor conferences in October:

View original post here:
Prevail Therapeutics to Present at Upcoming Investor Conferences

LIDDS Announces Data on Liproca Depot from Open Label Extension Study

UPPSALA, SWEDEN – LIDDS AB (publ) announced today results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28 % at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %.

Read the original post:
LIDDS Announces Data on Liproca Depot from Open Label Extension Study